Aiforia Technologies Oyj, together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software in Finland, the rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer; CE-IVD marked Aiforia clinical suite viewer for the clinical pathology workflow; and Aiforia Create, an agile solution to develop an AI model for image analysis application. The company’s products are used for the treatment of Parkinson’s disease, organ transplantation, and liver and inflammatory bowel diseases. It serves academic institutes and pharmaceutical companies through direct and partner sales. Aiforia Technologies Oyj was incorporated in 2013 and is headquartered in Helsinki, Finland.
Metrics to compare | AIFORIA | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipAIFORIAPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.8x | −2.7x | −0.5x | |
PEG Ratio | −0.65 | 0.07 | 0.00 | |
Price/Book | 6.4x | 2.6x | 2.6x | |
Price / LTM Sales | 36.9x | 2.1x | 3.3x | |
Upside (Analyst Target) | 25.7% | 28.6% | 45.1% | |
Fair Value Upside | Unlock | 5.0% | 7.4% | Unlock |